DEF: SBC Medical Group Holdings 2026 Annual Meeting Proxy Statement

SBC Medical Group Holdings Incorporated announces its 2026 Annual Meeting of Stockholders, to be held virtually on July 9, 2026, featuring director elections and charter amendments.

Summary

• SBC Medical Group Holdings Incorporated is holding its 2026 Annual Meeting of Stockholders virtually on July 9, 2026 (July 8, 2026, ET).
• The meeting agenda includes the election of four directors, ratification of Malone Bailey, LLP as the independent auditor for fiscal year 2026, and several proposals to amend and restate the company's Fifth Amended and Restated Certificate of Incorporation.
• Key proposed amendments to the charter include eliminating the plurality voting standard for director elections, removing the provision that directors can only be removed for cause, opting out of Delaware's anti-takeover statute (Section 203), providing exculpation for officers from personal liability for breach of fiduciary duty, and making other technical changes to modernize the charter.
• The record date for determining stockholders entitled to vote is May 20, 2026.
• The company is providing proxy materials primarily over the internet, with a Notice of Internet Availability of Proxy Materials sent on or about May 28, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and proposed amendments aimed at modernization and efficiency. The controlled company status and ongoing litigation introduce some cautionary elements.

Positives

• The company is holding a virtual annual meeting to increase stockholder attendance and participation globally, reduce costs, and minimize environmental impact.
• The proposed charter amendments aim to modernize corporate governance, align with best practices, and potentially reduce litigation costs.
• The board of directors is actively seeking a fifth independent director to further strengthen board oversight.
• The company has a robust Audit Committee composed of independent directors, with one member qualifying as a financial expert.

Negatives

• The company is a 'controlled company' as Dr. Yoshiyuki Aikawa controls approximately 81.7% of the voting power, meaning stockholders may not have the same protections as those in companies subject to all Nasdaq corporate governance requirements.
• A class action lawsuit has been filed challenging the provision in the Current Charter that directors may be removed only for cause, seeking a declaration that this provision is void and invalid.

Risks

• The company is a controlled company, with Dr. Yoshiyuki Aikawa holding approximately 81.7% of the voting power, which could limit minority shareholder influence.
• A class action lawsuit has been filed challenging the provision that directors may be removed only for cause, which could lead to legal costs and potential changes to corporate governance.
• The proposed opt-out of Section 203 of the DGCL could make the company more susceptible to hostile takeovers after a 12-month waiting period.
• The proposed exculpation of officers from personal liability for breach of fiduciary duty, while permitted by law, could reduce accountability for certain actions.
• The company's business operations involve significant related-party transactions, primarily with medical corporations where relatives of the CEO are members, which requires careful oversight to ensure terms are not less favorable than arm's length transactions.

Future Outlook

The company is holding its 2026 annual meeting to elect directors, ratify auditors, and approve amendments to its charter. The proposed charter amendments aim to modernize corporate governance, including changes to director elections, removal provisions, anti-takeover defenses, and officer liability.

Management Comments

• We believe hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our annual meeting.
• We believe this process expedites stockholders receipt of the materials, lowers the costs of the annual meeting and conserves natural resources.
• Whether you plan to attend the annual meeting or not, it is important that you cast your vote either in person or by proxy.
• We encourage you to vote your shares by submitting a proxy in advance of the annual meeting so that your shares will be represented and voted at the meeting, whether or not you can attend.
• The Board believes that its leadership structure currently serves the best interests of our shareholders, partners, customers, and other stakeholders because of Dr. Aikawas deep expertise in the Companys business.
• While the Board and its committees oversee risk management strategy, management is responsible for implementing and supervising day-to-day risk management processes and reporting to the Board and its committees on such matters.

Industry Context

StockSavvy.ai notes that the proposed charter amendments by SBC Medical Group Holdings Incorporated reflect a trend among publicly traded companies to enhance corporate governance flexibility and potentially reduce litigation risks. The move to a virtual meeting format is also a common practice adopted by many companies to improve accessibility and reduce costs.

Comparison to Industry Standards

• The proposed elimination of the plurality voting standard for director elections and the move towards majority voting aligns with evolving corporate governance best practices, as many S&P 500 companies have adopted majority voting policies.
• The proposal to opt out of Section 203 of the DGCL is a common strategy for companies seeking to reduce anti-takeover protections, which can be viewed by some investors as increasing flexibility for potential strategic transactions, while others may see it as reducing shareholder protections.
• The proposed exculpation of officers for breach of fiduciary duty aligns with recent amendments to Delaware law (effective August 1, 2022) that permit such provisions, aiming to attract and retain executive talent by limiting personal liability for certain actions, a practice seen across many Delaware corporations.
• The company's reliance on related-party transactions with medical corporations, where CEO's relatives are members, is a common structure in certain industries but requires rigorous oversight to ensure compliance with arm's length standards, a key concern for governance-focused investors.

Management Changes

Corporate Governance

Legal Proceedings

• A class action complaint was filed on February 11, 2026, against the Company and its board of directors in the Court of Chancery of the State of Delaware, captioned Keith Jones v. SBC Medical Group Holdings Incorporated, et al, C.A. No. 2026-0193-PAF (Del. Ch.). The complaint seeks a declaratory judgment that the provision of the Current Charter stating that any director or the entire board of directors may be removed from office only for cause violates Section 141(k) of the DGCL and Delaware common law.

Related Party Transactions

• The Company has entered into franchisor-franchisee contracts and service contracts with seven medical corporations (MCs) where relatives of the CEO are members. The Company also has equity interests in six of these MCs.
• The Company provides management and operational support services to Medical Corporation Misakikai and General Incorporated Association Miotokai following the acquisition of MB career lounge.
• The Company's subsidiaries have entered into business consignment agreements for management consulting and operational support services with Medical Corporation Association Furinkai and Medical Corporation Association Junikai.
• The Company's CEO, Dr. Yoshiyuki Aikawa, controls several entities (Hariver Inc., Skynet Academy Co., Ltd., Japan Medical & Beauty Inc., AI Med Inc., Co-medical Co., Ltd., SBC Inc., SBC Shonan Osteopathic Clinic Inc., General Incorporated Association SBC, SBC Tokyo Medical University, SBC Irvine MC, Waqoo, Inc., SBC Kijimadaira Resort Inc.) with which the Company has had transactions.
• The Company disposed of its subsidiaries SBC Kijimadaira Resort Inc. and Skynet Academy Co., Ltd. to entities controlled by the CEO.
• The Company entered into a memorandum of sale for an aircraft with General Incorporated Association SBC, an entity controlled by the CEO.
• The Company purchased unsecured convertible bonds issued by MEDIROM Healthcare Technologies Inc., where an independent director, Fumitoshi Fujiwara, serves as a Director and CFO.
• The Company paid officer compensation of approximately JPY240 million ($1,604,028) to Yoshiko Aikawa, the CEO's mother and CEO of the Company's subsidiaries.

Stakeholder Impact

• Shareholders will vote on director elections and significant amendments to the company's charter, impacting corporate governance and potential future strategic actions.
• The proposed charter amendments, particularly the opt-out of Section 203 and removal of 'for cause' director removal, could affect shareholder control and the company's susceptibility to takeovers.
• The exculpation of officers may reduce the risk of personal liability for management, potentially impacting the willingness of individuals to serve in executive roles.
• Related party transactions require careful scrutiny to ensure they are conducted on terms no less favorable than arm's length transactions, protecting the interests of all shareholders.

Next Steps

• Stockholders are urged to submit their proxies to vote in advance of the annual meeting.
• The company will publish final voting results in a Current Report on Form 8-K within four business days of the annual meeting.
• If Proposals 3-7 are approved, the company expects to file the Restated Charter with the Delaware Secretary of State promptly following the annual meeting.
• The company intends to increase the board size to five members and appoint a new independent director once a suitable candidate is identified.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, detailing standard corporate governance proposals and director elections. While the proposed charter amendments are significant, they are presented for shareholder vote and do not contain immediate financial performance data or strategic shifts that would warrant a strong buy or sell recommendation. The controlled company status and ongoing litigation are factors that warrant a 'hold' position, suggesting investors should monitor future developments.

Keywords

Proxy Statement, Annual Meeting, Stockholders, Board of Directors, Charter Amendment, Corporate Governance, Director Election, Independent Auditor, Malone Bailey, LLP, Section 203 DGCL, Plurality Voting, Removal for Cause, Officer Exculpation, Virtual Meeting, SBC Medical Group Holdings